COEP Stock Overview
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Coeptis Therapeutics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.37 |
| 52 Week High | US$2.19 |
| 52 Week Low | US$0.29 |
| Beta | -0.89 |
| 1 Month Change | 4.34% |
| 3 Month Change | -35.47% |
| 1 Year Change | -73.60% |
| 3 Year Change | -96.22% |
| 5 Year Change | n/a |
| Change since IPO | -96.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| COEP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.1% | -3.9% | -3.1% |
| 1Y | -73.6% | -1.8% | 20.9% |
Return vs Industry: COEP underperformed the US Biotechs industry which returned -0.2% over the past year.
Return vs Market: COEP underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| COEP volatility | |
|---|---|
| COEP Average Weekly Movement | 16.9% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: COEP's share price has been volatile over the past 3 months.
Volatility Over Time: COEP's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 6 | Dave Mehalick | coeptistx.com |
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn’s disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease.
Coeptis Therapeutics Holdings, Inc. Fundamentals Summary
| COEP fundamental statistics | |
|---|---|
| Market cap | US$15.11m |
| Earnings (TTM) | -US$21.27m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs COEP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COEP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$21.27m |
| Earnings | -US$21.27m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.59 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 26.1% |
How did COEP perform over the long term?
See historical performance and comparison